§
Luxuse
Patent Intelligence
Sign In
← Back to Patent Explorer
US4282229A Expired / Lapsed US ⏱️ 0.0 years remaining

Hydantoin derivatives as therapeutic agents

Assignee: Pfizer Inc
•
Filing: 1979-09-04
•
Granted: 1981-08-04
•
Expires: 1999-09-04
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A series of spiro-hydantoin compounds has been prepared by condensing the appropriate carbonyl ring compound, such as the corresponding 1-indanone, 1-tetralone, 4-chromanone, thiochroman-4-one, 7,8-dihydroquinolin-5(6H)-one, 6,7-dihydropyridin-5(5H)-one, thiondane-3-one-1,1-dioxide and 4-oxoisothiochroman-2,2-dioxide, respectively, with potassium cyanide and ammonium carbonate. The resulting hydantoin derivatives are found to be useful in preventing or alleviating chronic diabetic complications. Preferred member compounds include spiro-[imidazolidine-4,1'-indan]-2,5-dione, 6-fluoro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione, 6-chloro-spiro-[chroman-4,4'-imidazolidine]-2',5-dione, 6,7-dichloro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione, 6,8-dichloro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione, 6'-fluoro-spiro-[imidazolidine-4,4'-thiochroman]-2,5-dione and 6',7'-dichloro-spiro-[imidazolidine-4,4'-thiochroman]-2,5-dione.

Inventors

  • 👤 Reinhard Sarsas

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-03 12:31
CPC Classifications
C; C07; C07D; C07D235/00; C07D235/02; C07C; C07C323/00; C07D311/00; C07D311/02; C07D311/04; C07D311/22; C07D487/00; C07D487/02; C07D487/10; C07D491/00; C07D491/02; C07D491/10; C07D495/00; C07D495/02; C07D495/10

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 67 words
A method of treating a diabetic host to prevent or alleviate ocular and neuritic diabetes-associated chronic complications, which comprises orally, parenterally or topically administering to said host an effective amount of a compound selected from the group consisting of spiro-hydantoins of the formula: ##STR10## and the base salts thereof with pharmacologically acceptable cations, wherein W is --(CH 2 ) n -- and n is zero or one.
Claim 2
Independent Claim 67 words
A method of treating a diabetic host to prevent or alleviate ocular and neuritic diabetes-associated chronic complications, which comprises orally, parenterally or topically administering to said host an effective amount of a compound selected from the group consisting of spiro-hydantoins of the formula: ##STR10## and the base salts thereof with pharmacologically acceptable cations, wherein W is --(CH 2 ) n -- and n is zero or one.
Claim 3
Dependent Claim 13 words
The method as claimed in claim 1 wherein the compound administered is 6',7'-dihydro-spiro-[imidazolidine-4,5'(5H)-pyrindine]-2,5-dione.
Claim 4
Dependent Claim 13 words
The method as claimed in claim 1 wherein the compound administered is 7',8'-dihydro-spiro-[imidazolidine-4,5'(6H)-quinoline]-2,5-dione.
Claim 5
Dependent Claim 36 words
A composition suitable for oral administration comprising a pharmaceutically acceptable carrier and a compound of the formula as claimed in claim 1 in an amount effective for the treatment of ocular and neuritic diabetes-associated chronic complications.
Claim 6
Dependent Claim 11 words
The composition according to claim 4 wherein the compound is 6',7'-dihydro-spiro-[imidazolidine-4,5'(5H)-pyrindine]-2,5-dione.
Claim 7
Dependent Claim 11 words
The composition according to claim 4 wherein the compound is 7',8'-dihydro-spiro-[imidazolidine-4,5'-(6H)-quinoline]-2,5-dione.

References Cited (Backward Citations)

US3821383A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1984-08-03 1985-02-02 1985-08-04 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1988-08-03 1989-02-02 1989-08-04 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1992-08-03 1993-02-02 1993-08-04 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag